Suppr超能文献

他克莫司与羟丙甲纤维素和十二烷基硫酸钠形成固体分散体后口服吸收得到改善。

Improved oral absorption of tacrolimus by a solid dispersion with hypromellose and sodium lauryl sulfate.

作者信息

Jung Hyuck Jun, Ahn Hye In, Park Ji Yeon, Ho Myoung Jin, Lee Dae Ro, Cho Ha Ra, Park Jun Seo, Choi Yong Seok, Kang Myung Joo

机构信息

College of Pharmacy, Dankook University, 119 Dandae-ro, Dongnam-gu, Cheonan, Chungnam 330-714, South Korea.

College of Pharmacy, Dankook University, 119 Dandae-ro, Dongnam-gu, Cheonan, Chungnam 330-714, South Korea.

出版信息

Int J Biol Macromol. 2016 Feb;83:282-7. doi: 10.1016/j.ijbiomac.2015.11.063. Epub 2015 Nov 28.

Abstract

A novel surfactant-incorporated hydroxypropyl methylcellulose (HPMC) solid dispersion (SD) system was constructed in order to facilitate the release rate and oral absorption of tacrolimus (FK506), a poorly water-soluble immunosuppressant. Several emulsifiers including sodium lauryl sulfate (SLS), as drug release promotors, were employed with HPMC to fabricate SD using the solvent wetting method. The solid state characteristics using differential scanning calorimetry and X-ray powder diffraction, revealed that FK506 was molecularly distributed within all dispersions in amorphous form. The dissolution rates of FK506 in SLS-incorporated SDs were much higher than those in SDs prepared with HPMC alone, and even with stearoyl polyoxyl-32 glycerides or tocopheryl polyethylene glycol 1000 succinate. In particular, the greatest dissolution enhancement was obtained from the SD consisting of the drug, HPMC, and SLS in a weight ratio of 1:1:3, providing a 50-fold higher drug concentration within 15 min, compared with HPMC SD. In vivo absorption study in rats demonstrates that the optimized formula remarkably increased the oral absorption of FK506, providing about 4.0-fold greater bioavailability (p<0.05) compared with the marketed product (Prograf®, Astellas Pharma). These data suggest that a novel SLS/HPMC SD may be an advantageous dosage form of FK506, boosting the dissolution and absorption in gastrointestinal tract.

摘要

为了提高难溶性免疫抑制剂他克莫司(FK506)的释放速率和口服吸收,构建了一种新型的含表面活性剂羟丙基甲基纤维素(HPMC)固体分散体(SD)系统。使用溶剂湿润法,将包括十二烷基硫酸钠(SLS)在内的几种乳化剂作为药物释放促进剂与HPMC一起用于制备SD。差示扫描量热法和X射线粉末衍射分析的固态特性表明,FK506以无定形形式分子分散在所有分散体中。FK506在含SLS的SD中的溶解速率远高于仅用HPMC制备的SD,甚至高于用硬脂酰聚氧乙烯-32甘油酯或聚乙二醇1000维生素E琥珀酸酯制备的SD。特别是,由药物、HPMC和SLS按重量比1:1:3组成的SD获得了最大的溶解增强效果,与HPMC SD相比,在15分钟内药物浓度提高了50倍。大鼠体内吸收研究表明,优化后的配方显著提高了FK506的口服吸收,与市售产品(普乐可复®,安斯泰来制药)相比,生物利用度提高了约4.0倍(p<0.05)。这些数据表明,新型的SLS/HPMC SD可能是FK506的一种优势剂型,可促进其在胃肠道中的溶解和吸收。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验